What Should Be Prepared Before Medical Device Registration Renewal in South Korea?

Before proceeding with a medical device registration renewal in South Korea, a company should first confirm the target country, product risk class, applicable regulatory pathway, and current documentation basis. It should then assess the technical file, quality management system, labeling and instructions for use, local agent or authorized representative arrangements, clinical evidence, and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, incomplete documents, or unclear authorization arrangements. For South Korea, this includes confirming the renewal pathway and current requirements of the Ministry of Food and Drug Safety (MFDS).

Published: 2026-07-15 17:41; Updated: 2026-07-15 17:41

Key Summary

For the question of what to prepare before medical device registration renewal in South Korea, companies should first confirm the target country, product risk level, applicable regulatory pathway, and existing documentation basis, and then evaluate technical files, quality management system, labels and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends a documentation gap assessment before formal submission to avoid prolonged project timelines due to unclear classification, documents, or authorization arrangements. For Chinese medical device manufacturers, a more reliable approach is to first conduct product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused.

Target-market registration usually affects the technical file, authorized representative, importer cooperation, labeling language, QMS evidence, and subsequent change maintenance. If the project is advanced only by asking which documents to submit, corrections or rework are likely in model coverage, evidence chain consistency, labeling claims, and certificate control rights. AIMEILI recommends planning this issue within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than recreating documents on an ad hoc basis for each country.

This article is compiled from the AIMEILI registration practice question bank, medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country regulatory authority and the product documentation basis.

Applicable Scenarios and Core Questions

Companies searching for what to prepare before medical device registration renewal in South Korea usually want to solve not a conceptual explanation, but whether existing documents can support target-market submission, whether a local agent or authorized representative is needed, why timelines may be extended, and which issues may affect the launch plan. Behind this question are often product classification, registration pathway, evidence chain, labeling localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for one country alone is not enough. A more valuable approach is to first make the core technical file, QMS evidence, performance verification, clinical evidence, and labeling and instructions for use into reusable versions, and then localize them according to each country's regulatory requirements.

Registration Judgment Logic

Companies should first confirm the product intended use, mechanism of action, use scenario, body contact method, duration of use, whether it is sterile, whether it is active, and whether it contains software or IVD attributes, and then determine the risk class and submission pathway. If the pathway judgment is wrong, subsequent translation, notarization, authorization, testing, and supplementary documents will all deviate.

For a target-market project, the applicant entity and local responsibility boundaries should also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documents. If these issues are handled vaguely only in commercial contracts, they can easily affect market control rights later.

Documents and Evidence

Common documents include product description, model specification matrix, intended use, risk classification basis, ISO 13485 or applicable QMS evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labeling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance materials.

The key to document quality is not quantity but consistency. Instructions for use claims, model coverage in test reports, applicable scope of clinical evidence, risk management conclusions, labeling warnings, and registration application form information must support one another. Regulatory authorities focus on whether the product is safe, effective, and traceable for the intended use, not on how many documents the company has uploaded.

Common Errors

• The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Translating domestic NMPA documents directly and submitting them without rearranging evidence according to the target-market pathway.
• Having too many model specifications but insufficient coverage in test reports, clinical evidence, or labeling.
• Selecting a local agent only based on sales cooperation, without clarifying regulatory responsibilities, certificate control rights, and post-market maintenance responsibilities.
• Inconsistent claims across labeling, instructions for use, promotional materials, and registration documents, leading to deficiency corrections or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, resulting in repeated preparation in each country and amplified cost and timelines.

Company Preparation Checklist

Before starting the project, companies should use an internal checklist to confirm the documentation basis, so that key evidence gaps are not discovered only after submission begins.

• Organize the target product list, model specification matrix, and intended use statement.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions for use.
• Confirm the responsibilities, fees, certificate control rights, and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Viewpoint

AIMEILI recommends that companies not understand target-market registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, first establishing a clear core technical file and evidence matrix and then converting it according to national requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than supplementing documents on a country-by-country basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway judgment; second, consistency of the document evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documents appear numerous, the project may still experience repeated issues during deficiency corrections, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documents be used directly for target-market registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, labeling adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent usually participates in registration communication, changes, renewal, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such a registration project, companies should establish a project ledger and manage the product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and estimated submission time in the same table. This helps identify document gaps in time and allows management to judge whether the project will affect the launch plan.

For companies that already have registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which documents must be reissued or supplemented according to national requirements. In particular, labeling and instructions for use, clinical evaluation, risk management, performance verification, and QMS certificates must maintain version consistency.

• Confirm the target market and product list.
• Complete risk classification and pathway judgment.
• Establish a document gap assessment table.
• Clarify the local agent and certificate control rights.
• Track translation, notarization, testing, and deficiency correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality Management System and Evidence Consistency

From a registration review perspective, QMS documents are not an isolated certificate. Regulatory authorities usually check whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the declared product, or if the manufacturing address, model specifications, or instructions for use version are inconsistent with test reports, the company may be asked for supplementary explanations even if it has prepared many documents.

Companies should establish an evidence consistency checklist before submission, matching product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling and instructions for use version, and QMS certificate item by item. This action appears basic but can significantly reduce the probability of deficiency corrections, especially for projects submitted simultaneously in multiple GHWP member states or for multiple product series.

Localization Conversion and Agent Responsibilities

Target-market registration projects usually involve local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control rights and subsequent market stability.

Labels, instructions for use, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact information. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a new isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining certificates but neglect post-market maintenance. Once a manufacturing address change, model expansion, instructions for use update, or agent replacement occurs, the certificate can easily become disconnected from market sales.

AIMEILI recommends that companies manage this issue within an annual international registration plan: first clarify target-market priorities, then establish a reusable document package and country gap list, and finally arrange submission, deficiency correction, post-market maintenance, and renewal milestones. The value of doing so is not only improving registration efficiency in a single country, but more importantly enabling companies to develop replicable overseas compliance capabilities and reduce the cost of organizing documents from scratch each time they enter a new market.

Further Reading

Previous: When must registration changes be notified for medical device registration in South Korea?

Next: How are multiple models grouped for medical device registration in South Korea?

Recommended reading:

• How to choose a local agent for medical device registration in Brazil?
• How are authorized representative responsibilities divided for medical device registration in Brazil?
• Why does the medical device registration cycle in Brazil become extended?
• What are common reasons for deficiency corrections in Brazilian medical device registration documents?
• How is post-market surveillance conducted for medical device registration in Brazil?
• When must registration changes be notified for medical device registration in Brazil?

Back to FAQ Center

News and Insights

Contact AIMEILI

Content Review and Applicable Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary judgment.

Applicable boundaries: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the official requirements of the target country regulatory authority, testing conclusions, or legal opinions.